XERS (xerispharma.com) Prakiraan pendapatan perusahaan

Xeris Biopharma Holdings, Inc. - logo grafis emiten XERS

Xeris Biopharma (XERS) has focused on organic growth and cost optimization, eschewing new acquisitions. The company's target sales level demonstrates commercial potential, with the current value equal to 0.37. Business success relies on insurance coverage and the recognition of injectable products. However, international expansion is hindered by geopolitical risks and complexities regarding overseas patent protection.

XERS - Pendapatan mangsa ngarep perusahaan Xeris Pharma ing rentang 04.07.2022 - 17.11.2026

Rincian metrik keuangan lan pasar Xeris Pharma (XERS)

Analisis fundamental perusahaan:xerispharma.com
Produk mawa merek Xeris Biopharma Inc

This indicator assesses the fundamental resilience of the business by modeling future cash flows, filtering out market noise and identifying hidden risks of capital stagnation. The analysis of projected sales for Xeris Biopharma (XERS) is based on the aggregation of demand rates and market potential, which is critical for Xeris Biopharma in the context of the commercial rollout of innovative injections and securing insurance coverage for its drugs.

Analisis perusahaan pesaing

Volume dodolan mangsa ngarep perusahaan VRTX (Vertex)|ALNY (Alnylam Pharmaceuticals, Inc.) - Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan Insmed INSM|UTHR (United Therapeutics Corp.) - Pendapatan sing dikarepake perusahaan|BioMarin Pharmaceutical - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan BBIO (BridgeBio Pharma, Inc.)|BGM Group Corp (BGM) - Prakiraan pendapatan perusahaan|Cogent Biosciences Inc (COGT) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan Keros Pharma|ARCT: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan etonpharma.com (ETON)|Volume dodolan mangsa ngarep perusahaan Kamada Ltd. KMDA|Prakiraan volume dodolan FULC (fulcrumtx.com)|Prakiraan volume dodolan Abeona ABEO|MREO - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan PLX (Protalix BioTherapeutics, Inc)|Pliant Therapeutics Inc (PLRX) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan APLT (appliedtherapeutics.com)|RNTX (Rein Therapeutics Inc.) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan GELS|Volume dodolan mangsa ngarep perusahaan AYTU (aytubio.com)|Volume dodolan mangsa ngarep perusahaan Chemomab Therapeutics Ltd CMMB|Prakiraan volume dodolan SRXH (SRx Health Solutions Inc.)|Pendapatan mangsa ngarep perusahaan PLRZ|AEZS - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan CYTH (CTD Holdings)|INZY: Prakiraan volume dodolan|Pendapatan sing dikarepake perusahaan RPHM (Reneo Pharma)|Prakiraan pendapatan perusahaan cosciensbio.com